A Phase 4 interventional study of Tripliam (perindopril, indapamide, amlodipine) and Reaptan (perindopril, amlodipine) in Arterial Hypertension, sponsored by University of Roma La Sapienza. Status unknown at 1 site in Italy. Per ClinicalTrials.gov, last updated 2016-03-17.
Sponsored by University of Roma La Sapienza · Phase 4, Interventional, and Treatment
The aim of the study is to compare the efficacy and safety of low-dose combination of three antihypertensive drugs versus fixed high-dose combination of two antihypertensive drugs in arterial hypertension
The aim of the study is to compare the efficacy and safety of commercially available low-dose combination of three antihypertensive drugs versus commercially available fixed high-dose combination of two antihypertensive drugs in arterial hypertension
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's planned enrollment of 100 is above the median of 90 across 4,995 interventional studies indexed under Hypertension.
Browse Hypertension studies →University of Roma La Sapienza is the lead sponsor of 388 studies on the registry; 55 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with arterial hypertension resistant to monotherapy
Exclusion Criteria:
None
Patients will be treated with Tripliam, that is a commercially available fixed low-dose combination of three antihypertensive drugs, that is 5 mg/daily perindopril, 1,25 mg/daily indapamide and 5 mg/day amlodipine
Drug: Tripliam (perindopril, indapamide, amlodipine)
Patients will be treated with Reaptan, that is a commercially available fixed high-dose combination of two antihypertensive drugs, that is 10 mg/daily perindopril and 5 mg/day amlodipine
Drug: Reaptan (perindopril, amlodipine)
Fixed combination of perindopril 5 mg, indapamide 1,25 and amlodipine 5 mg
Also known as: Combination of three antihypertensive drugs
Fixed combination of perindopril 10 mg and amlodipine 5 mg
Also known as: Combination of two antihypertensive drugs
Number of patients who reach target blood pressure
How many patients have blood pressure within normal limits
Time frame: From baseline to the end of the 3-month study period
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Roma La Sapienza